Cargando…

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

SUMMARY: In this post hoc analysis, we assessed romosozumab efficacy and safety in European patients enrolled in FRAME. Romosozumab treatment through 12 months, followed by denosumab for a further 24 months, resulted in early and sustained risk reduction for major fracture categories, associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langdahl, Bente, Hofbauer, Lorenz C., Ferrari, Serge, Wang, Zhenxun, Fahrleitner-Pammer, Astrid, Gielen, Evelien, Lakatos, Péter, Czerwinski, Edward, Gimeno, Esteban Jódar, Timoshanko, Jen, Oates, Mary, Libanati, Cesar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652294/ https://www.ncbi.nlm.nih.gov/pubmed/36173415 http://dx.doi.org/10.1007/s00198-022-06544-2

Ejemplares similares

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
por: Kendler, D.L., et al.
Publicado: (2019)

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
por: Brown, Jacques P., et al.
Publicado: (2021)

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
por: Miyauchi, Akimitsu, et al.
Publicado: (2019)

Romosozumab for osteoporosis
Publicado: (2021)

Effectiveness of Teriparatide in Women Over 75 Years of Age with Severe Osteoporosis: 36-Month Results from the European Forsteo Observational Study (EFOS)
por: Walsh, J. Bernard, et al.
Publicado: (2012)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS)
por: Langdahl, Bente L., et al.
Publicado: (2009)

Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study
por: Ljunggren, Östen, et al.
Publicado: (2013)

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
por: Poole, Kenneth ES, et al.
Publicado: (2021)

Romosozumab and cardiovascular safety in Japan
por: Takeuchi, Yasuhiro
Publicado: (2021)

Bone - a casualty of ICU survival?
por: Amrein, Karin, et al.
Publicado: (2015)

FGF23 in Acute and Chronic Illness
por: Schnedl, Christian, et al.
Publicado: (2015)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Profile of romosozumab and its potential in the management of osteoporosis
por: Lim, Sian Yik, et al.
Publicado: (2017)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Vitamin D deficiency following Billroth II surgery - How much vitamin D is enough?: a case report
por: Sampl, Eva, et al.
Publicado: (2010)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
por: McClung, M. R., et al.
Publicado: (2020)

Preparing the Leaders of Tomorrow: Learnings from a Two-Year Community of Practice in Fragility Fractures
por: Murray, Suzanne, et al.
Publicado: (2022)

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study
por: Inose, Hiroyuki, et al.
Publicado: (2022)

Prescreening for Osteoporosis With Quantitative Ultrasound in Postmenopausal White Women
por: Steiner, Bernhard, et al.
Publicado: (2018)

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study
por: McCloskey, E. V., et al.
Publicado: (2021)

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
por: Jódar-Gimeno, Esteban
Publicado: (2007)

Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures
por: Gimeno, Esteban Jódar
Publicado: (2012)

Romosozumab, clinical trials, and real-world care of patients with osteoporosis
por: Lewiecki, E. Michael
Publicado: (2020)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
por: Lim, Sian Yik
Publicado: (2022)

Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis
por: Trepanowski, Nicole, et al.
Publicado: (2023)

The Bone-Cardiovascular Axis: Mechanisms and Clinical Relevance
por: Verheyen, Nicolas, et al.
Publicado: (2018)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

SAT-LB71 Is Late Diagnosis of Postsurgical Hypoparathyroidism the Rule, Not the Exception?
por: Fahrleitner-Pammer, Astrid, et al.
Publicado: (2020)

Total Hip Bone Mineral Density as an Indicator of Fracture Risk in Bisphosphonate‐Treated Patients in a Real‐World Setting
por: Banefelt, Jonas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_be3b8riqsdan8aiqce6vgf990h